PMID- 23440867
OWN - NLM
STAT- MEDLINE
DCOM- 20130919
LR  - 20220330
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 73
IP  - 4
DP  - 2013 Mar
TI  - Promising new molecular targeted therapies in head and neck cancer.
PG  - 315-25
LID - 10.1007/s40265-013-0025-3 [doi]
AB  - Despite advances in multimodality therapies for the treatment of squamous cell 
      carcinoma of the head and neck (SCCHN), survival rates, functional outcomes and 
      toxicities of therapy remain poor. The recognition of the prognostic value of 
      human papillomavirus (HPV) status, and the advent of biologically targeted 
      therapies with potential for decreased toxicities and increased selectivity, 
      represent significant developments in our understanding of SCCHN. Targeted agents 
      currently approved or under investigation for SCCHN include epidermal growth 
      factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, 
      zalutumumab, nimotuzumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, 
      lapatinib, afatanib, dacomitinib), vascular endothelial growth factor receptor 
      (VEGFR) inhibitors (bevacizumab, sorafenib, sunitinib, vandetanib) and various 
      inhibitors of other pathways and targets, including phosphatidylinositol 3' 
      kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), MET and insulin-like 
      growth factor receptor (IGF-1R). On-going clinical trials are evaluating these 
      emerging agents and their combinations in the treatment of SCCHN.
FAU - Dorsey, Kelly
AU  - Dorsey K
AD  - Robert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology, 
      Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.
FAU - Agulnik, Mark
AU  - Agulnik M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Squamous Cell/*drug therapy
MH  - Clinical Trials as Topic
MH  - ErbB Receptors/*antagonists & inhibitors/therapeutic use
MH  - Head and Neck Neoplasms/*drug therapy
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors/therapeutic use
EDAT- 2013/02/27 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/02/27 06:00
PHST- 2013/02/27 06:00 [entrez]
PHST- 2013/02/27 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
AID - 10.1007/s40265-013-0025-3 [doi]
PST - ppublish
SO  - Drugs. 2013 Mar;73(4):315-25. doi: 10.1007/s40265-013-0025-3.